These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38748285)

  • 1. Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors.
    Fan Z; Liu X; Wang N; Yu S; Bi C; Si Y; Ling X; Liu C; Wang J; Sun H
    J Cancer Res Clin Oncol; 2024 May; 150(5):253. PubMed ID: 38748285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
    Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
    Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
    Zhou C; Kang D; Xu Y; Zhang L; Zha X
    Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
    Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the binding mode of a novel LSD1 inhibitor by molecular docking and molecular dynamics simulations.
    Zhang X; Li M; Wang Y; Zhao Y
    J Recept Signal Transduct Res; 2015; 35(5):363-9. PubMed ID: 26364657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
    Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
    Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
    J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annual review of LSD1/KDM1A inhibitors in 2020.
    Fu DJ; Li J; Yu B
    Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
    Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.
    Yin Z; Liu S; Yang X; Chen M; Du J; Liu H; Yang L
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
    Ma Y; Zheng Y; Ji Y; Wang X; Ye B
    Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
    [No Abstract]   [Full Text] [Related]  

  • 17. 3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.
    Ding L; Wang ZZ; Sun XD; Yang J; Ma CY; Li W; Liu HM
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3521-3528. PubMed ID: 28610981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
    Ota Y; Kakizawa T; Itoh Y; Suzuki T
    Molecules; 2018 May; 23(5):. PubMed ID: 29734782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mining the Dynamical Properties of Substrate and FAD Binding Pockets of LSD1: Hints for New Inhibitor Design Direction.
    Yang K; Liu H
    J Chem Inf Model; 2024 Jun; 64(12):4773-4780. PubMed ID: 38837697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.